Premium
The metabolic response to glucagon and glucagon‐(1‐21)‐peptide in normal subjects and non insulin dependent diabetics.
Author(s) -
Owens DR,
Vora J,
Morris T,
Luzio S,
Ryder RE,
Atiea J,
Hayes TM
Publication year - 1986
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1986.tb02894.x
Subject(s) - glucagon , medicine , endocrinology , insulin , glucagon like peptide 1 , pancreatic hormone , hormone , peptide hormone , diabetes mellitus , insulin resistance , type 2 diabetes
The metabolic effects of glucagon leading to hyperglycaemia are well recognised. However, the spasmolytic properties of glucagon have only relatively recently been utilised in clinical medicine. The marked hyperglycaemia accompanying the smooth muscle relaxant action of glucagon has led to the development of smaller peptides derived from glucagon which may retain the spasmolytic effects without the metabolic consequences. This study compares the metabolic and hormonal response to one such peptide, glucagon‐(1‐21)‐peptide, with the parent peptide glucagon. The results demonstrate that glucagon‐(1‐21)‐peptide has no metabolic effects comparable to glucagon. In normal subjects and non‐ insulin dependent diabetics, glucagon‐(1‐21)‐peptide has no stimulatory effect on the pancreatic beta‐cell.